A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

NCT05033691 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
EGFR Gene Mutation
EGF-R Positive Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Brain Metastases

Interventions

RADIATION: Stereotactic surgery

Sponsor

Hadassah Medical Organization